These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 17011503)

  • 1. Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance.
    Agostini M; Schoenmakers E; Mitchell C; Szatmari I; Savage D; Smith A; Rajanayagam O; Semple R; Luan J; Bath L; Zalin A; Labib M; Kumar S; Simpson H; Blom D; Marais D; Schwabe J; Barroso I; Trembath R; Wareham N; Nagy L; Gurnell M; O'Rahilly S; Chatterjee K
    Cell Metab; 2006 Oct; 4(4):303-11. PubMed ID: 17011503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons from human mutations in PPARgamma.
    Hegele RA
    Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen.
    Cock TA; Back J; Elefteriou F; Karsenty G; Kastner P; Chan S; Auwerx J
    EMBO Rep; 2004 Oct; 5(10):1007-12. PubMed ID: 15359271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
    Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fat Mass Reduction With Adipocyte Hypertrophy and Insulin Resistance in Heterozygous PPARγ Mutant Rats.
    Gumbilai V; Ebihara K; Aizawa-Abe M; Ebihara C; Zhao M; Yamamoto Y; Mashimo T; Hosoda K; Serikawa T; Nakao K
    Diabetes; 2016 Oct; 65(10):2954-65. PubMed ID: 27381370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dominant negative peroxisome proliferator-activated receptor-gamma knock-in mouse exhibits features of the metabolic syndrome.
    Freedman BD; Lee EJ; Park Y; Jameson JL
    J Biol Chem; 2005 Apr; 280(17):17118-25. PubMed ID: 15716267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C).
    Visser ME; Kropman E; Kranendonk ME; Koppen A; Hamers N; Stroes ES; Kalkhoven E; Monajemi H
    Diabetologia; 2011 Jul; 54(7):1639-44. PubMed ID: 21479595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nervous System Expression of PPARγ and Mutant PPARγ Has Profound Effects on Metabolic Regulation and Brain Development.
    Stump M; Guo DF; Lu KT; Mukohda M; Cassell MD; Norris AW; Rahmouni K; Sigmund CD
    Endocrinology; 2016 Nov; 157(11):4266-4275. PubMed ID: 27575030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterozygous deletion of Seipin in islet beta cells of male mice has an impact on insulin synthesis and secretion through reduced PPARγ expression.
    Xiong J; Sun P; Wang Y; Hua X; Song W; Wang Y; Wu J; Yu W; Liu G; Chen L
    Diabetologia; 2020 Feb; 63(2):338-350. PubMed ID: 31776610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dominant negative human peroxisome proliferator-activated receptor (PPAR){alpha} is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms.
    Semple RK; Meirhaeghe A; Vidal-Puig AJ; Schwabe JW; Wiggins D; Gibbons GF; Gurnell M; Chatterjee VK; O'Rahilly S
    Endocrinology; 2005 Apr; 146(4):1871-82. PubMed ID: 15661858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inguinal Fat Compensates Whole Body Metabolic Functionality in Partially Lipodystrophic Mice with Reduced PPARγ Expression.
    Chang CS; Yu SS; Ho LC; Chao SH; Chou TY; Shao AN; Kao LZ; Chang CY; Chen YH; Wu MS; Tsai PJ; Maeda N; Tsai YS
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor-gamma and insulin action: insights from human genetics.
    Chatterjee VK
    Horm Res; 2003; 60 Suppl 3():51-5. PubMed ID: 14671397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPARγ lipodystrophy mutants reveal intermolecular interactions required for enhancer activation.
    Madsen MS; Broekema MF; Madsen MR; Koppen A; Borgman A; Gräwe C; Thomsen EGK; Westland D; Kranendonk MEG; Koerkamp MG; Hamers N; Bonvin AMJJ; Pittol JMR; Natarajan KN; Kersten S; Holstege FCP; Monajemi H; van Mil SWC; Vermeulen M; Kragelund BB; Cassiman D; Mandrup S; Kalkhoven E
    Nat Commun; 2022 Nov; 13(1):7090. PubMed ID: 36402763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-inflammatory Macrophages suppress PPARγ activity in Adipocytes via S-nitrosylation.
    Yin R; Fang L; Li Y; Xue P; Li Y; Guan Y; Chang Y; Chen C; Wang N
    Free Radic Biol Med; 2015 Dec; 89():895-905. PubMed ID: 26475041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of genetic variation of PPARgamma in humans.
    Meirhaeghe A; Amouyel P
    Mol Genet Metab; 2004; 83(1-2):93-102. PubMed ID: 15464424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of phospholipase PLAAT3 causes a mixed lipodystrophic and neurological syndrome due to impaired PPARγ signaling.
    Schuermans N; El Chehadeh S; Hemelsoet D; Gautheron J; Vantyghem MC; Nouioua S; Tazir M; Vigouroux C; Auclair M; Bogaert E; Dufour S; Okawa F; Hilbert P; Van Doninck N; Taquet MC; Rosseel T; De Clercq G; Debackere E; Van Haverbeke C; Cherif FR; Urtizberea JA; Chanson JB; Funalot B; Authier FJ; Kaya S; Terryn W; Callens S; Depypere B; Van Dorpe J; ; Poppe B; Impens F; Mizushima N; Depienne C; Jéru I; Dermaut B
    Nat Genet; 2023 Nov; 55(11):1929-1940. PubMed ID: 37919452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARγ mutations, lipodystrophy and diabetes.
    Astapova O; Leff T
    Horm Mol Biol Clin Investig; 2014 Nov; 20(2):63-70. PubMed ID: 25460295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality.
    Duan SZ; Ivashchenko CY; Whitesall SE; D'Alecy LG; Duquaine DC; Brosius FC; Gonzalez FJ; Vinson C; Pierre MA; Milstone DS; Mortensen RM
    J Clin Invest; 2007 Mar; 117(3):812-22. PubMed ID: 17304352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central players in inherited lipodystrophies.
    Jeninga EH; Kalkhoven E
    Trends Endocrinol Metab; 2010 Oct; 21(10):581-8. PubMed ID: 20621503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
    Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.